DISTINCTIONS. This year sees two newcomers from the University of Gothenburg on the Clarivate Analytics list of the world’s most cited researchers: Nicholas Ashton and Deliang Chen. In total, 14 of our researchers now belong to the top percentage of those most frequently cited by other researchers. Nicholas Ashton is a researcher at the Institute of Neuroscience and Physiology, working within clinical neurochemistry. As a relatively young researcher, it feels…
Kaj Blennow receives international research award
AWARD. This year, Copenhagen University Hospital – Rigshospitalet’s International KFJ Award goes to Swedish Professor Kaj Blennow, who is recognized as a global leader in the development of biomarkers for the diagnosis of Alzheimer’s disease. The use of biomarkers in clinical practice and research is rapidly advancing in healthcare. In the field of neurodegenerative diseases, such as Alzheimer’s disease, Swedish Professor Kaj Blennow is one of the forefront figures in…
New blood test gives very high accuracy to screen for Alzheimer’s disease
NEW STUDY. A new blood test called p-tau217 shows promise as an Alzheimer’s disease biomarker, and when used in a two-step workflow very high accuracy to either identify or exclude brain amyloidosis, the most important and earliest pathology. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues at University of Lund and in Montreal, Canada. In recent years, a lot of effort has…
New blood test differentiates neurodegeneration in Alzheimer’s disease from other dementias
NEW STUDY. A new blood test that can track and follow the neurodegeneration in Alzheimer’s disease – and exclude other dementias. That is an innovation now presented by researchers at the University of Gothenburg, together with colleagues in Italy and USA. In recent years, a lot of effort has been put on developing biomarkers in blood that could potentially help to diagnose and monitor Alzheimer’s disease (AD). Tau – one…
Optimal blood tests for development of new therapies of Alzheimer’s disease
NEW STUDY. A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and another blood test that is optimal for detecting relevant treatment effects. These findings will speed up the development of new therapies that can slow down the disease progression. The Swedish study lead by Professor Oskar Hanssson, Lund University, and Professor Kaj Blennow, University of Gothenburg, looked at several newly…